相似文献
1
The Treatment of Inflammatory Bowel Disease in Patients With a History of Malignancy.
Inflamm Bowel Dis. 2019 May 4;25(6):998-1005. doi: 10.1093/ibd/izy376.
2
[Effect of Immunomodulators and Biologic Agents on Malignancy in Patients with Inflammatory Bowel Disease].
Korean J Gastroenterol. 2017 Oct 25;70(4):162-168. doi: 10.4166/kjg.2017.70.4.162.
3
Risk of Lymphoma, Colorectal and Skin Cancer in Patients with IBD Treated with Immunomodulators and Biologics: A Quebec Claims Database Study.
Inflamm Bowel Dis. 2015 Aug;21(8):1847-53. doi: 10.1097/MIB.0000000000000457.
4
The risk of lymphoma in the treatment of inflammatory bowel disease with immunosuppressive agents.
Crit Rev Oncol Hematol. 2005 Oct;56(1):169-78. doi: 10.1016/j.critrevonc.2005.02.004.
5
Do inflammatory bowel disease therapies cause cancer?
Inflamm Bowel Dis. 2013 May;19(6):1306-21. doi: 10.1097/MIB.0b013e3182807618.
6
Advanced therapy for inflammatory bowel disease: a guide for the primary care physician.
J Am Board Fam Med. 2014 May-Jun;27(3):411-20. doi: 10.3122/jabfm.2014.03.130224.
7
Review article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel disease.
Aliment Pharmacol Ther. 2013 Nov;38(9):1002-24. doi: 10.1111/apt.12491. Epub 2013 Sep 25.
8
What Should Be Done in Inflammatory Bowel Disease Patients with Prior Malignancy?
Dig Dis. 2017;35(1-2):50-55. doi: 10.1159/000449083. Epub 2017 Feb 1.
9
Previous cancer and/or lymphoma in patients with refractory IBD--pro: anti-TNF or immunosuppressive treatment.
Dig Dis. 2014;32 Suppl 1:116-21. doi: 10.1159/000367861. Epub 2014 Dec 17.
10
Safety and Efficacy of Biologic Agents for the Management of Inflammatory Bowel Disease After Liver Transplantation.
Pharmacotherapy. 2017 Dec;37(12):1578-1585. doi: 10.1002/phar.2036. Epub 2017 Nov 21.
引用本文的文献
1
Small Bowel Carcinoma in the Setting of Inflammatory Bowel Disease.
Clin Colon Rectal Surg. 2023 Mar 15;37(1):46-52. doi: 10.1055/s-0043-1762929. eCollection 2024 Jan.
2
Crohn's disease and breast cancer: a literature review of the mechanisms and treatment.
Intern Emerg Med. 2023 Aug;18(5):1303-1316. doi: 10.1007/s11739-023-03281-0. Epub 2023 May 3.
3
Therapeutic Management of Adults with Inflammatory Bowel Disease and Malignancies: A Clinical Challenge.
Cancers (Basel). 2023 Jan 16;15(2):542. doi: 10.3390/cancers15020542.
4
Inflammatory bowel disease-associated malignancies and considerations for radiation impacting bowel: a scoping review.
J Gastrointest Oncol. 2022 Oct;13(5):2565-2582. doi: 10.21037/jgo-22-138.
5
The Recurrence of Cervical Precancerous Lesion Among HIV Positive and Negative Ethiopian Women After Cryotherapy: A Retrospective Cohort Study.
Cancer Control. 2022 Jan-Dec;29:10732748221129708. doi: 10.1177/10732748221129708.
6
The Complex Interplay Between Inflammatory Bowel Disease and Malignancy.
Curr Gastroenterol Rep. 2020 Feb 13;22(3):13. doi: 10.1007/s11894-020-0747-9.
本文引用的文献
1
Lymphoma Risk and Overall Safety Profile of Adalimumab in Patients With Crohn's Disease With up to 6 Years of Follow-Up in the Pyramid Registry.
Am J Gastroenterol. 2018 Jun;113(6):872-882. doi: 10.1038/s41395-018-0098-4. Epub 2018 Jun 5.
2
Tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: long-term safety and efficacy in an open-label extension study.
Br J Dermatol. 2018 Oct;179(4):853-862. doi: 10.1111/bjd.16798. Epub 2018 Aug 13.
3
Infliximab for Crohn's Disease: More Than 13 Years of Real-world Experience.
Inflamm Bowel Dis. 2018 Feb 15;24(3):490-501. doi: 10.1093/ibd/izx072.
4
Neoplasia and Precursor Lesions of the Female Genital Tract in IBD: Epidemiology, Role of Immunosuppressants, and Clinical Implications.
Inflamm Bowel Dis. 2018 Feb 15;24(3):510-531. doi: 10.1093/ibd/izx062.
5
Risk of malignancy associated with paediatric use of tumour necrosis factor inhibitors.
Ann Rheum Dis. 2018 Jul;77(7):1012-1016. doi: 10.1136/annrheumdis-2017-212613. Epub 2018 Feb 9.
6
Long-term efficacy and safety of ustekinumab in 122 refractory Crohn's disease patients: a multicentre experience.
Aliment Pharmacol Ther. 2018 Mar;47(5):588-595. doi: 10.1111/apt.14487. Epub 2018 Jan 8.
7
Risk of Malignancy in a Nationwide Cohort of Elderly Inflammatory Bowel Disease Patients.
Drugs Aging. 2017 Nov;34(11):859-868. doi: 10.1007/s40266-017-0498-y.
8
Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease.
JAMA. 2017 Nov 7;318(17):1679-1686. doi: 10.1001/jama.2017.16071.
9
Lymphoma in the Tofacitinib Rheumatoid Arthritis Clinical Development Program.
Arthritis Care Res (Hoboken). 2018 May;70(5):685-694. doi: 10.1002/acr.23421. Epub 2018 Apr 2.
10
Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry.
J Am Acad Dermatol. 2017 Nov;77(5):845-854.e5. doi: 10.1016/j.jaad.2017.07.013. Epub 2017 Sep 8.
Zotero 插件